BREAKING NEWS
This content is not available in your region

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial
Text size Aa Aa

(Reuters) – AstraZeneca’s <AZN.L> first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.

Fasenra failed to meet its target in the final-stage trial, named Galathea, this month.

(Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.